Hypercalcemia Management

Diagnosis and Initial Treatment

• The American Society of Clinical Oncology recommends obtaining a 25-OH Vitamin D level to evaluate for symptoms of hypercalcemia, such as confusion, lethargy, nausea, vomiting, constipation, polyuria, and dehydration 1
• Aggressive hydration with normal saline is recommended as the initial treatment for hypercalcemia, with a target urine output of 100-150 mL/hour, to correct dehydration and promote calciuresis, as recommended by the American Thoracic Society and the Annals of Oncology 2, 3, 4

Medical Therapy

• Bisphosphonates are the mainstay of treatment for hypercalcemia, with zoledronic acid 4 mg IV or pamidronate 60-90 mg IV as alternative options, according to the European Society for Medical Oncology 3
• The following table summarizes the treatment options for hypercalcemia:

• Calcitonin may be used for rapid but short-term calcium reduction, and glucocorticoids may also be considered, as suggested by the European Society for Medical Oncology 3
• Denosumab 120 mg SC can be considered if hypercalcemia persists despite other measures, and is safe in renal impairment, as recommended by the National Comprehensive Cancer Network and the American Journal of Kidney Diseases 5, 4
• Calcimimetics, such as cinacalcet, may be beneficial in hyperparathyroidism-related hypercalcemia, as recommended by the Annals of Internal Medicine 6

Surgical Intervention

• Parathyroidectomy is recommended for patients with primary hyperparathyroidism who meet surgical criteria, according to the American College of Surgeons 1

Maintenance Therapy

• Maintenance bisphosphonate therapy may be considered for patients with malignancy-associated hypercalcemia, as recommended by the European Society for Medical Oncology 3
• The American Journal of Kidney Diseases recommends discontinuing any calcium supplements or calcium-based phosphate binders in patients with hypercalcemia to prevent worsening of the condition 4
• Volume depletion can worsen both hypercalcemia and renal function, emphasizing the importance of adequate hydration, as stated by the American Journal of Kidney Diseases 7

Monitoring and Complications

• Daily laboratory monitoring of serum calcium, renal function, and electrolytes is essential in managing hypercalcemia, as recommended by the American Journal of Kidney Diseases 4
• Serum calcium levels should be monitored every 1-2 days until stable, and electrolytes, particularly magnesium and potassium, should be followed, as recommended by the National Comprehensive Cancer Network and the Annals of Oncology 5, 3
• Regular monitoring of renal function is essential, especially when using bisphosphonates, as recommended by the European Hematology Association and the National Comprehensive Cancer Network 8, 5, 3
• Volume status assessment, including daily weights and careful intake and output monitoring, is crucial in preventing fluid overload, as recommended by the American Journal of Kidney Diseases 7
• Excessive fluid administration can lead to fluid overload, particularly in patients with a history of cirrhosis with ascites, emphasizing the importance of careful fluid management, as recommended by the American Journal of Kidney Diseases 4
• Administering loop diuretics before adequate hydration can worsen volume depletion and renal function, as stated by the American Journal of Kidney Diseases 7
• Neglecting to monitor electrolytes can lead to hypokalemia and hypomagnesemia, worsening symptoms and complications of hypercalcemia, as recommended by the National Comprehensive Cancer Network and the Annals of Oncology 5, 3
• Delaying treatment can result in rapid worsening of renal function, emphasizing the importance of prompt intervention, as recommended by the American Journal of Kidney Diseases and the National Comprehensive Cancer Network 7, 5